Publication & Citation Trends
Publications
0 total
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity OA
Cited by 62
Semantic Scholar
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody OA
Cited by 10
Semantic Scholar
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics OA
Cited by 140
Semantic Scholar
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer OA
Cited by 64
Semantic Scholar
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer OA
Cited by 7
Semantic Scholar
Abstract 2667: In vitro properties and pre-clinical activity of PF-06801591, a high-affinity engineered anti-human PD-1
Cited by 5
Semantic Scholar
Therapeutic Protein Drug–Drug Interactions
Cited by 0
Semantic Scholar
RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models OA
Cited by 84
Semantic Scholar
Research Topics
Monoclonal and Polyclonal Antibodies Research
(31)
Immune Cell Function and Interaction
(29)
Cancer Immunotherapy and Biomarkers
(24)
Immunotherapy and Immune Responses
(12)
Biosimilars and Bioanalytical Methods
(8)
Affiliations
Novartis (Switzerland)
Merck & Co., Inc., Rahway, NJ, USA (United States)
Biogen (United States)
Amgen (United States)
Center for Drug Evaluation and Research